Foxy-5 (TFA)

Foxy-5 (TFA)

• UNSPSC Description: Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model[1][2][3].
• Target Antigen: Wnt
• Type: Peptides
• Related Pathways: Stem Cell/Wnt
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/foxy-5-tfa.html
• Purity: 99.02
• Solubility: H2O : 2 mg/mL (ultrasonic)
• Smiles: O=C([C@H](CS)NC(CNC([C@H](CC(O)=O)NC([C@@H](NC=O)CCSC)=O)=O)=O)N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC(C)C)=O.OC(C(F)(F)F)=O
• Molecular Weight: 808.80
• References & Citations: [1]Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.|[2]Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.|[3]Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.J Neuroinflammation. 2024 Mar 26;21(1):75.|Patent. US20230130144A1.|Pathol Res Pract. 2024 May 26:259:155369.|Int J Oral Sci. 2024 Feb 19;16(1):15.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
• Clinical Information: Phase 2